Drug Update · Pulmonology

FDA Approves Tezepelumab for Severe Asthma: Rate Ratio 0.44 in NAVIGATOR

July 10, 2026

Primary efficacy (annualized exacerbation rate)

0.93 with tezepelumab vs 2.10 with placebo (rate ratio 0.44; 95% CI 0.37-0.53) [1]

Efficacy in eosinophils <300 cells/µL

1.02 with tezepelumab vs 1.73 with placebo (rate ratio 0.59; 95% CI 0.46-0.75) [1]

Approved dose (label)

210 mg subcutaneously every 4 weeks [8][12]

FDA initial approval date

2021-12-17 (FDA original approval date) [12]

Clinical Perspective

Pulmonologists and other clinicians treating severe, uncontrolled asthma in patients aged 12 years and older now have an FDA‑approved TSLP‑blocking biologic option supported by the NAVIGATOR 52‑week exacerbation trial ^[1]^[5]. The source‑confirmed data support use as add‑on maintenance therapy to reduce annualized exacerbation rates and to improve lung function and patient‑reported outcomes across biomarker subgroups, including patients with baseline blood eosinophils <300 cells/µL ^[1]. Clinicians should consider the labeled safety profile, including hypersensitivity and injection site reactions, when selecting patients and planning administration ^[2]^[3]^[4].

Dr. Nikhil Chatterjee, MBBS, MD (Respiratory Medicine) · Pulmonology

Tezepelumab (TEZSPIRE) was approved by the FDA for the add-on maintenance treatment of severe asthma in patients 12 years and older; the approval reflects data from the 52-week NAVIGATOR trial in which tezepelumab lowered the annualized rate of asthma exacerbations to 0.93 versus 2.10 with placebo (rate ratio, 0.44; 95% CI, 0.37 to 0.53) ^[1]^[5]. The FDA approval was based on these phase 3 efficacy results and supporting safety and labeling data ^[1]^[5].

Clinical Context

Tezepelumab (tezepelumab-ekko; brand TEZSPIRE) is a human monoclonal antibody that binds thymic stromal lymphopoietin (TSLP), an epithelial‑cell–derived cytokine implicated in airway inflammation; blocking TSLP reduces multiple downstream inflammatory biomarkers ^[1]^[5]. The product is marketed under TEZSPIRE and developed by Amgen and AstraZeneca collaborators per trial and label authorship ^[1]^[5]. The agent is positioned as an add-on maintenance biologic for patients with severe, uncontrolled asthma aged 12 years and older, administered by subcutaneous injection per the approved label ^[4]^[5]. The FDA initial U.S. approval date is listed as 2021-12-17 in regulatory records ^[5].

Key Findings

The NAVIGATOR phase 3 trial randomized 1,061 patients to tezepelumab 210 mg subcutaneously every 4 weeks or placebo for 52 weeks and used the annualized rate of clinically significant asthma exacerbations over 52 weeks as the primary end point ^[1]. Clinicians should consult current prescribing information for full dosing guidance. In NAVIGATOR the annualized exacerbation rate was 0.93 with tezepelumab versus 2.10 with placebo (rate ratio, 0.44; 95% CI, 0.37 to 0.53; P<0.001) ^[1]. The trial also reported results in a lower‑eosinophil subgroup: for patients with baseline blood eosinophils <300 cells per microliter, annualized rates were 1.02 with tezepelumab and 1.73 with placebo (rate ratio, 0.59; 95% CI, 0.46 to 0.75; P<0.001) ^[1]. Secondary endpoints in NAVIGATOR showed greater improvements at week 52 with tezepelumab than placebo for prebronchodilator FEV1 (difference, 0.13 L; 95% CI, 0.08 to 0.18; P<0.001) and for symptom and quality‑of‑life instruments including ACQ-6, AQLQ, and ASD ^[1]. These efficacy results contributed to the FDA approval for add-on maintenance treatment in patients 12 years and older ^[1]^[5].

Safety & Tolerability

Hypersensitivity reactions, including rash and allergic conjunctivitis, were observed in clinical trials, and postmarketing cases of anaphylaxis have been reported ^[3]^[4].
Injection site reactions (e.g., injection site erythema, swelling, pain) occurred at a rate of 3.3% in patients treated with TEZSPIRE versus 2.7% with placebo in the pooled PATHWAY and NAVIGATOR safety population; in an open‑label trial, injection site reactions were observed in 5.7% of patients using the pre‑filled pen and 0% with the pre‑filled syringe, noting the trial was not designed for a formal comparison between devices ^[2].
Adverse reactions listed in the prescribing information and labels include pharyngitis, arthralgia, back pain, nasopharyngitis, upper respiratory tract infection, epistaxis, influenza, and injection site reactions ^[2]^[4].

Study Design

NAVIGATOR was a randomized, double‑blind, placebo‑controlled phase 3 multicenter trial of 52 weeks’ duration that enrolled 1,061 patients 12 to 80 years of age with severe, uncontrolled asthma; patients were randomized to tezepelumab 210 mg subcutaneously every 4 weeks or placebo and the primary endpoint was the annualized rate of asthma exacerbations over 52 weeks ^[1]. Clinicians should consult current prescribing information for full dosing guidance. The FDA reviewed NAVIGATOR and related data leading to initial U.S. approval in 2021 and labeling updates thereafter ^[1]^[5].

FAQ

What is tezepelumab (TEZSPIRE) approved for?

Tezepelumab (TEZSPIRE) is approved by the FDA for the add‑on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. The approval is based on randomized double‑blind trials, including NAVIGATOR, that assessed exacerbation rates, lung function, and patient‑reported outcomes over 52 weeks.

How does tezepelumab work?

Tezepelumab is a human monoclonal antibody that binds thymic stromal lymphopoietin (TSLP), an epithelial‑cell–derived cytokine upstream in airway inflammatory cascades. Blocking TSLP reduces multiple downstream inflammatory biomarkers and cytokines associated with asthma pathophysiology; the precise mechanism mediating clinical benefit has not been definitively established in the label.

What is the recommended dose of tezepelumab?

The recommended dosage of TEZSPIRE is 210 mg administered subcutaneously once every 4 weeks, with formulations including vial, pre‑filled syringe, and pre‑filled pen described in the prescribing information. NAVIGATOR evaluated 210 mg subcutaneously every 4 weeks as the regimen used for efficacy assessment. Clinicians should consult current prescribing information for complete dosing guidance.

What are the known side effects of tezepelumab?

The prescribing information and trial reports list adverse reactions observed with TEZSPIRE, including pharyngitis, arthralgia, back pain, nasopharyngitis, upper respiratory tract infection, epistaxis, influenza, and injection site reactions. Hypersensitivity reactions (e.g., rash, allergic conjunctivitis) occurred in clinical trials and postmarketing reports have included anaphylaxis; clinicians should be aware of these reactions and the label guidance on management and patient counseling.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Tezepelumab for Severe Asthma: Rate Ratio 0.44 in NAVIGATOR

FDA Approves Tezepelumab for Severe Asthma: Rate Ratio 0.44 in NAVIGATOR

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Pulmonology in your inbox.

Related Clinical Updates

Mepolizumab: Severe Asthma Rate Ratio 0.47 (MENSA)

FDA Approves depemokimab for Severe Eosinophilic Asthma: Rate Ratio 0.42

dupilumab: FDA Approves for COPD; FEV1 Improved 0.09 L in BOREAS

Verified HCP Portal